Literature DB >> 12962273

A role for antibodies in tumor immunity.

Ronald C Kennedy1, Michael H Shearer.   

Abstract

Recent advances have demonstrated the clinical utility of specific monoclonal antibodies that recognize tumor-associated antigens on the surface of the tumor cell in the treatment of breast cancer and B cell lymphoma in humans. In addition to these studies, an experimental tumor model, where antibodies that recognize a viral-encoded tumor-specific antigen play a major role in tumor immunity, will be discussed. Together, these studies implicate antibodies as a means of providing tumor immunity against some cancers. The necessity for designing cancer vaccines that induce antibodies with specificity for antigens on the tumor cell will be discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12962273     DOI: 10.1080/08830180305222

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  4 in total

1.  Tumor immunity against a simian virus 40 oncoprotein requires CD8+ T lymphocytes in the effector immune phase.

Authors:  Devin B Lowe; Michael H Shearer; Cynthia A Jumper; Robert K Bright; Ronald C Kennedy
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

2.  Fc gamma receptors play a dominant role in protective tumor immunity against a virus-encoded tumor-specific antigen in a murine model of experimental pulmonary metastases.

Authors:  Devin B Lowe; Michael H Shearer; Cynthia A Jumper; Robert K Bright; Ronald C Kennedy
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

3.  Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help.

Authors:  Natalia Savelyeva; Catherine A King; Ellen S Vitetta; Freda K Stevenson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-21       Impact factor: 11.205

4.  Detection of brain-directed autoantibodies in the serum of non-small cell lung cancer patients.

Authors:  Manoj Banjara; Chaitali Ghosh; Aaron Dadas; Peter Mazzone; Damir Janigro
Journal:  PLoS One       Date:  2017-07-26       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.